PEER-REVIEWED PUBLICATIONS

Development of an actionable framework to address cancer care disparities in medically underserved populations in the United States: expert roundtable recommendations.  Karen M. Winkfield, Jeanne M. Regnante, Ellen Miller-Sonet, Evelyn T. González, Karen M. Freund, and Patricia M. Doykos. JCO Oncology Practice. 2021 March; 17(3): e278-e293 doi: 10.1200/OP.20.00630. Epub 2021 Jan 19.

Operational strategies in US cancer centers of excellence that support the successful accrual of racial and ethnic minorities in clinical trials. Regnante JM, Richie N, Fashoyin-Aje L, Hall LL, Highsmith Q, Louis J, Turner K, Hoover S, Lee S, González E, Williams EAdams H IIIObasaju C, Sargeant I, Spinner J, Reddick C, Gandee M, Geday M, Dang JT, Watson R, Chen M Jr. Contemporary Clinical Trials Communications. 2020 March; 17: ISSN 2451-8654. doi: 10.1016/j.con.ctc.2020.100532.

Reducing uninformative IND safety reports: a list of serious adverse events anticipated to occur in patients with lung cancer. Bonomi P, Stuccio N, Delgra CJ, Ferris AE, et al. Ther Innov Regul Sci (2020).

Expanding access to lung cancer clinical trials by reducing the use of restrictive exclusion criteria: perspectives of a multistakeholder working group. Forde PM, Bonomi P, Shaw A, Blumenthal GM, Ferris A, Patel C, Melemed A, Basu Roy U, Ramamoorthy A, Liu Q, Burns T, Gainor JF, Lovly C, Piotrowska Z, Lehman J, Selig W. Clin Lung Cancer. 2020 Feb 26. pii: S1525-7304(20)30033-4.

Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: results from an online survey of patients with solid tumors. Epstein RS, Aapro MS, Basu Roy UK, Salimi T, Krenitsky J, Leone-Perkins ML, Girman C, Schlusser C, Crawford J. Adv Ther. 2020 Aug;37(8):3606-3618. doi: 10.1007/s12325-020-01419-6. Epub 2020 Jul 8.

The promise of immuno-oncology: implications for defining the value of cancer treatment. Kaufman HL, Atkins MB, Subedi P, Wu J, Chambers J, Joseph Mattingly T 2nd, Campbell JD, Allen J, Ferris AE, Schilsky RL, Danielson D, Lichtenfeld JL, House L, Selig WKD. J Immunother Cancer. 2019 May 17;7(1):129. doi: 10.1186/s40425-019-0594-0.

US Cancer Centers of Excellence Strategies for Increased Inclusion of Racial and Ethnic Minorities in Clinical Trials. Regnante JM, Richie NA, Fashoyin-Aje L, Vichnin M, Ford M, Basu Roy U, Turner K, Hall LL, Gonzalez E, Esnaola N, Clark LT, Adams HC 3rd, Alese OB, Gogineni K, McNeill L, Petereit D, Sargeant I, Dang J, Obasaju C, Highsmith Q, Lee SC, Hoover SC, Williams EL, Chen MS Jr. J Oncol Pract. 2019 Apr;15(4):e289-e299. doi: 10.1200/JOP.18.00638. Epub 2019 Mar 4.

Updates Regarding Biomarker Testing for Non-Small Cell Lung Cancer - Considerations from the National Lung Cancer Roundtable. Kim ES, Roy UB, Ersek JL, King J, Smith RA, Martin N, Martins R, Moore A, Silvestri GA, Jett J. J Thorac Oncol. 2019 Mar;14(3):338-342. doi: 10.1016/j.jtho.2019.01.002. Epub 2019 Jan 30.

Learning from Patients - Reflections on Use of Patient-Reported Outcomes in Lung Cancer Trials. - Basu Roy U, King-Kallimanis BL, Kluetz PG, Selig W, Ferris A. J Thorac Oncol. 2018 Dec;13(12):1815-1817. doi: 10.1016/j.jtho.2018.09.003. Epub 2018 Oct 15.

Project Transform: engaging patient advocates to share their perspectives on improving research, treatment, and policy. Bridges JFP, Janssen EM, Ferris A, Dy SM. Curr Med Res Opin. 2018 Oct;34(10):1755-1762. doi: 10.1080/03007995.2018.1440199. Epub 2018 Mar 9.

The Society of Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, Dubinett SM, Ferris A, Gandhi L, Garon EB, Hellmann MD, Hirsch FR, Malik S, Neal JW, Papadimitrakopoulou VA, Rimm DL, Schwartz LH, Sepesi B, Yeap BY, Rizvi NA, Herbst RS. J Immunother Cancer. 2018 Jul 17;6(1):75. doi: 10.1186/s40425-018-0382-2.

Making lung cancer clinical trials more inclusive: recommendations for expanding eligibility criteria. Bonomi P, Blumenthal G, Stern Ferris A, Stewart DJ, Selig WKD, Krug LM, Allen J, Ison G, Langer CJ, Melemed A, Odogwu L, Basu Roy U, Sandler A. J Thorac Oncol. 2018 Jun;13(6):748-751. doi: 10.1016/j.jtho.2018.02.013.

American Society of Clinical Oncology Statement: biosimilars in oncology. Lyman GH, Balaban E, Diaz M, Ferris A, Tsao A, Voest E, Zon R, Francisco M, Green S, Sherwood S, Harvey RD, Schilsky RL. J Clin Oncol. 2018 Apr 20;36(12):1260-1265. doi: 10.1200/JCO.2017.77.4893. Epub 2018 Feb 14.

Live, learn, pass it on: a patient advocacy engagement project on the lived experience of lung cancer survivors. Dy SM, Janssen EM, Ferris A, Bridges JFP. J Patient Exp. 2017 Dec;4(4):162-168. doi: 10.1177/2374373517714451. Epub 2017 Jun 16.

Clinician perspectives on current issues in lung cancer drug development. Waqar SN, Bonomi PD, Govindan R, Hirsch FR, Riely GJ, Papadimitrakopoulou V, Kazandjian D, Khozin S, Larkins E, Dickson DJ, Malik S, Horn L, Ferris A, Shaw AT, Jänne PA, Mok TS, Herbst R, Keegan P, Pazdur R, Blumenthal GM. J Thorac Oncol. 2016 Sep;11(9):1387-96. doi: 10.1016/j.jtho.2016.05.009.

Understanding the experience of living with non-small-cell lung cancer (NSCLC): a qualitative study. Buzaglo J, Gayer C, Mallick R, Charap E, Ferris A, Golant M, Langer C, Morris A, Mullins CD, Cella D. J Community Support Oncol. 2014 Jan;12(1):6-12.

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM. Clinical Cancer Res. 2009 Sep 1;15(17):5323-37. doi: 10.1158/1078-0432.CCR-09-0737.

WHITE PAPERS

Burden of financial toxicity of lung cancer treatment: Understanding the patient and caregiver perspective. LUNGevity Foundation, 2019

Willingness to perform multiple biopsies to improve quality of lung cancer care: Understanding the oncologists’ perspective. LUNGevity Foundation, 2018

Reaching the Unreached: HCP Attitudes on and Usage of Patient Education Materials. LUNGevity Foundation, 2017

Treating cachexia-anorexia in lung cancer patients: understanding the patient perspective on novel treatment approaches. LUNGevity Foundation, 2016

Willingness for multiple biopsies to improve quality of lung cancer care: Understanding the patient perspective. LUNGevity Foundation, 2016

Need for consistent language around biomarker testing in the diagnosis and treatment of lung cancer. LUNGevity Foundation, 2015